Managing gastric cancer risk in lynch syndrome: controversies and recommendations

C. Richard Boland1 · Matthew B. Yurgelun2 · Kathryn A. Mraz3 · Patrick M. Boland4

Received: 29 January 2021 / Accepted: 9 February 2021 / Published online: 21 February 2021 © The Author(s) 2021

Introduction

Lynch syndrome is the hereditary predisposition to several cancers caused by pathogenic variants in the germline of certain DNA mismatch repair (MMR) genes: MSH2 (and EpCAM), MLH1, MSH6 and PMS2 [1]. The greatest risks are for colorectal cancer and endometrial cancer, but other organs are also at increased risk for cancer at earlier than expected ages [2]. Surveillance colonoscopy every 1–3 years and timely gynecological surgery can significantly decrease cancer mortality in patients with Lynch syndrome. Managing cancer risk in other organs is more controversial, and a variety of management regimens have been suggested over time by different expert panels.

Gastric cancer in Lynch syndrome

Gastric cancer in Lynch syndrome has been a controversial risk problem for a variety of reasons. The initial report of this disease occurred in 1913, when Warthin reported “Cancer Family G”. In the first reported generation of this family, gastric cancer and colorectal cancer each caused the deaths of two individuals. When the pathogenic germline variant in MSH2 was found, the family was followed up over seven generations, and gastric cancer was the third most common malignancy in the family, although that cancer decreased in frequency over the course of the twentieth century [3]. Gastric cancer fell in incidence throughout the twentieth century in US and European populations, and perhaps this provides some explanation for why it may have fallen in Lynch syndrome families as well. The problem here is that the reported incidence of gastric cancer in Lynch syndrome ranges from 6 to 13% [4], but there may be changes in incidence over the last 100 years, and there are certainly different incidences in geographical locations or ethnic groups that have a higher background incidence of this disease [5]. The data are scant, but 62–79% of gastric cancers in Lynch syndrome are intestinal type, whereas 23–32% are reported to be diffuse or poorly differentiated; some registries do not have information on all of the tumors [6, 7]. The tumors occur in the cardia, body and antrum of the stomach [4, 7].

Surveillance recommendations for gastric cancer risk in patients with Lynch syndrome

At this time, the most effective way to surveille patients for upper gastrointestinal cancer is through esophago-gastro-duodenoscopy (EGD). This approach permits early diagnosis in asymptomatic patients, but unlike the colon, there are no premalignant lesions to remove and reduce cancer incidence. The questions are at what age one should begin surveillance, how frequently to repeat it, and whether it is possible to
identify specific subgroups of patients with Lynch syndrome for whom a different regimen is appropriate. In light of the variable estimates of the risk of gastric cancer in this setting, one challenge is to determine what threshold of cancer risk is required to trigger an invasive surveillance program. Most expert panels have suggested that endoscopic surveillance is appropriate, but recommendations differ concerning the age to initiate surveillance and the frequency of repeating the exams; moreover, some groups advise against surveillance programs (Table 1) [8–16].

Recent research on the subject of EGDs in patients with Lynch syndrome

To help illuminate this problem, Ladigan-Badura et al. evaluated the effectiveness of EGD surveillance in patients with Lynch syndrome using data from the German Consortium for Familial Intestinal Cancer that dates back to 1999 [4]. In this prospective (but non-randomized) multi-cohort study of 2009 registered people with Lynch syndrome, 1128 underwent 5176 upper endoscopic exams at the time of their surveillance colonoscopies, which were typically done every 1–3 years. The investigators observed 49 gastric cancers in 47 patients. Patients undergoing surveillance EGDs were significantly more likely to be diagnosed with early stage disease (IUC 1a-1b) than in those diagnosed because of symptoms (83% vs 25%, P = 0.23). Most of the patients (68%) reported no family history of gastric cancer. The median age for the diagnosis of gastric cancer was 51 years (range 28–66), and 13 (28%) were younger than age 45. Almost all cases were in patients with pathogenic variants in MSH2 or MLH1; one was related to MSH6, one with EpCAM, and none were reported in PMS2 patients. Males made up 62% of the gastric cancer group. The authors conclude that finding significantly fewer advanced gastric cancers demonstrates the effectiveness of screening EGDs, and recommended routine surveillance in Lynch syndrome beginning at age 30.

The role of H. pylori and gastritis

An issue not addressed here is the value of testing for H. pylori infection at the time of the EGD. Although this does not add serious time or morbidity to an EGD and is listed in virtually all of the guidelines (Table 1), there is not much evidence that this is actually helpful. A recent study by Kumar et al. reported that in their cohort of 295 patients with Lynch syndrome who underwent 660 EGDs, 6 gastric cancers were found (2.8%), and just 6 in the whole cohort (again 2.8%) were H. pylori carriers. Although not specifically stated in the publication, none of the gastric cancers occurred in the context of a H. pylori infection (personal communication, BW Katona) [17]. This group also reported that 4 of the 5 upper gastrointestinal cancers detected on surveillance occurred within 2 years of the prior EGD [17]. Perhaps surveillance intervals require additional scrutiny. Equivalent rates of H pylori infection have been reported for patients with Lynch syndrome with or without a first degree relative gastric cancer [18]. Also, it has been recently reported in a small series that gastric cancer in Lynch syndrome is associated with underlying chronic autoimmune

Table 1  Surveillance recommendations for gastric cancer prevention in Lynch syndrome

| Organization | Age to consider beginning EGD | Surveillance Interval | Helicobacter pylori testing? | Other |
|--------------|-------------------------------|-----------------------|-----------------------------|-------|
| ACG [10]     | 30–35 years                   | 3–5 years (see recommendation under Other) | Yes, and treat positives | Surveillance if positive family history of GC or duodenal cancer |
| ASCO [11]    | Not stated                     | 1–3 years in high risk populations | Yes, and treat positives | Endorsed ESMO guidelines |
| EHTG [8]     | Not recommended                | Not recommended       | Yes                         | Consider surveillance in countries with increased GC (Korea, Japan) |
| ESDO [12]    | 30 years                      | 1–2 years in all patients | Yes                         |                   |
| ESGE [16]    | Not recommended                | Not recommended       | Yes                         |                   |
| ESMO [12]    | Not stated                     | 1–3 years (see recommendation under Other) | Yes | Surveillance in “high-risk populations” |
| NCCN [14]    | 40 years                      | 3–5 years in all patients | Yes, with each EGD | Asian patients may benefit from surveillance |
| USMSTF [15]  | 30–35 years                   | 2–3 years             | Yes (biopsy)                | Surveillance based upon “patient risk factors” |

Adapted from Kim et al. [9]

ACG American College of Gastroenterology, ASCO American Society for Clinical Oncology, EHTG European Hereditary Tumour Group (formerly the Mallorca Group), ESDO European Society of Digestive Oncology, ESGE European Society of Gastrointestinal Endoscopy, ESMO European Society for Medical Oncology, NCCN National Comprehensive Cancer Network, USMSTF United States Multisociety Task Force, UGI upper gastrointestinal, GC gastric cancer
gastritis unrelated to *H. pylori* infection, which opens another avenue for screening and risk assessment [19].

**Proposed conclusions**

What can the reader conclude from the study by Ladijan-Badura and colleagues? First, it takes a lot of EGDs to find early stage asymptomatic gastric cancers in Lynch syndrome. A diagnosis of gastric cancer was made in only 47/2009 (2.3%) of all their patients and in 48/5176 (0.93%) of their exams. That is a lot of negative exams. However, given the lethality of an advanced gastric cancer, this may be acceptable, especially since the exam could be done on an already sedated patient who is in the endoscopy suite for a colonoscopy, which should add only a few minutes and minimal morbidity to the effort. Secondly, the findings here and elsewhere [6] indicate that only a minority of individuals with Lynch syndrome-associated gastric cancer will have a family history of gastric cancer. Although a recent study found that a patient with Lynch syndrome is significantly and incrementally more likely to develop gastric cancer when there are first degree relatives with gastric cancer, more than two thirds of patients with Lynch syndrome-associated gastric cancers have no family history, so a reliance on this finding alone to guide EGD surveillance would likely miss the majority of cases [9]. Additionally, there would appear to be reason to focus this surveillance on patients with Lynch syndrome who carry pathogenic variants in *MSH2*, *MLH1* and (probably) *EpCAM*, but not do this on patients with *MSH6* pathogenic variants (probably) and *PMS2* (certainly). Using large genetic testing panels will also lead to the identification of lower penetrance genes and pathological variants in genes that are not suspected to raise the risk of gastric cancer. Future research is required to determine the optimal response to these situations [20].

**Final caveat**

Finally, this work stems from a European population, and one cannot assume that the data would be similar in countries with very high risks for gastric cancer, such as Japan and Korea, where the clinical picture appears to be quite different [21].

**Acknowledgements** Grant support includes research funding from Janssen Pharmaceuticals to MBY, the Utah Department of Health Cancer Genomics Program to KAM, and R01 CA72851 (“Familial and Early Onset CRC”) to CRB.

**Author contributions** Initial draft by CRB, consultation and editing from MBY, KAM and PMB.

**Compliance with ethical standards**

**Conflict of interest** CRB is a consultant for Ambry Genetics. MBY has a one-time consulting/Scientific Advisory Board honorarium from Janssen Pharmaceuticals, research funding from Janssen Pharmaceuticals, and is a paid consultant to UpToDate. PMB and KAM have no conflicts to report.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Peltomaki P, Olkinuora A, Nieminen TT (2020) Updates in the field of hereditary nonpolyposis colorectal cancer. Expert Rev Gastroenterol Hepatol 14:707–720
2. Peltomaki P (2016) Update on Lynch syndrome genomics. Fam Cancer 15:385–393
3. Douglas JA, Gruber SB, Meister KA et al (2005) History and molecular genetics of Lynch syndrome in family G: a century later. JAMA 294:2195–2202
4. Ladigan-Badura S, Vangala DB, Engel C et al (2021) Value of upper gastrointestinal endoscopy for gastric cancer surveillance in patients with Lynch syndrome. Int J Cancer 148:106–114
5. Shah SC, McKinley M, Gupta S, Peek RM Jr, Martinez ME, Gomez SL (2020) Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older. Gastroenterology 159(1705–14):e2
6. Capelle LG, Van Grieken NC, Lingsma HF et al (2010) Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138:487–492
7. Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ (1997) Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 74:551–555
8. Seppala TT, Latchford A, Negoi I et al (2020) European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg. https://doi.org/10.1002/bjs.11902
9. Kim J, Braun D, Ukaegbu C et al (2020) Clinical factors associated with gastric cancer in individuals with Lynch syndrome. Clin Gastroenterol Hepatol 18(830–7):e1
10. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110:223–262
11. Stoffel EM, Mangu PB, Gruber SB et al (2015) Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 33:209–217
12. Vangala DB, Cauchin E, Balmana J et al (2018) Screening and surveillance in hereditary gastrointestinal cancers: recommendations
from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. Eur J Cancer 104:91–103

13. Balmana J, Balaguer F, Cervantes A, Arnold D (2013) Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 24(Suppl 6):73–80

14. NCCN Clinical Practice Guideline in Oncology (2018) Genetic/ Familial high-risk assessment: Colorectal. Version 2.2019-July 30, 2018. NCCN.org. Accessed Version 2

15. Giardiello FM, Allen JI, Axilbund JE et al (2014) Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147:502–526

16. van Leerdam ME, Roos VH, van Hooft JE et al (2019) Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 51:1082–1093

17. Kumar S, Dudzik CM, Reed M, Long JM, Wangensteen KJ, Katona BW (2020) Upper endoscopic surveillance in lynch syndrome detects gastric and duodenal adenocarcinomas. Cancer Prev Res (Phila) 13:1047–1054

18. Soer EC, Leicher LW, Langers AM et al (2016) Equivalent Helicobacter pylori infection rates in Lynch syndrome mutation carriers with and without a first-degree relative with gastric cancer. Int J Colorectal Dis 31:693–697

19. Adar T, Friedman M, Rodgers LH, Shannon KM, Zukerberg LR, Chung DC (2019) Gastric cancer in Lynch syndrome is associated with underlying immune gastritis. J Med Genet 56:844–845

20. Cavaille M, Uhrhammer N, Privat M et al (2021) Feedback of extended panel sequencing in 1530 patients referred for suspicion of hereditary predisposition to adult cancers. Clin Genet 99:166–175

21. Saita C, Yamaguchi T, Horiguchi SI et al (2018) Tumor development in Japanese patients with Lynch syndrome. PLoS ONE 13:e0195572

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.